The best antibodies are defined by what they do, not how tightly they bind

The problem

The antibody industry lacks the tools to efficiently analyze every possible candidate. This leads to ‘passable’ drugs that suffer from limitations in dosing, administration, safety and efficacy.

The solution

Instead of relying on binding or affinity as a proxy, OCMS screens hundreds of thousands of antibodies directly for functional activity and selects the ones that actually drive the desired biological effect.

This matters because binding strength and biological performance often diverge. OCMS has found the most effective antibodies in their screens are not the strongest binders, underscoring a common industry pitfall: optimizing for affinity can miss the molecules that matter most. OCMS avoids that gap by putting function at the center of discovery from the very beginning.